Navigation Links
Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
Date:2/19/2013

NEW YORK, Feb. 19, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI") today announced the completion of a Phase I single rising dose study of its phosphodiesterase 1 (PDE1) inhibitor, ITI-214.  ITI-214, a novel, first-in-class selective PDE1 inhibitor, was discovered by ITI and is in development under an exclusive collaboration with Takeda Pharmaceutical Company Limited for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). 

The primary objectives of the Phase I study were to determine the safety, tolerability and pharmacokinetic profile of single oral doses of ITI-214 in healthy volunteers.  The study was conducted as a randomized, double-blind, placebo-controlled study in 70 subjects.  The results indicated that ITI-214 was safe and well-tolerated across a broad range of single oral doses.  Moreover, ITI-214 demonstrates a favorable pharmacokinetic profile consistent with once-a-day dosing. The study represents a significant milestone as it is the first demonstration of the safety of a PDE1 inhibitor in a Phase 1 clinical trial.

"We are pleased with the advancement of ITI-214 in clinical development," stated Sharon Mates , Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies.  "The data obtained for ITI-214 support its continued development for the treatment of Cognitive Impairment Associated with Schizophrenia and other neuropsychiatric and neurological disorders."

About Schizophrenia

Schizophrenia is a major neuropsychiatric disorder that affects over one percent of the world population with an illness that begins in late adolescence and lasts a lifetime. Its best known symptoms are "positive symptoms", which include hallucinations and delusions; but other mental functions are also affected, including social and motivational skills ("negative symptoms") and cognitive behaviors, like ina
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
2. Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015
3. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
4. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
5. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
6. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
7. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
8. Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
9. Growing Prevalence of Asthma is Fueling Vigorous Industry Competition for Effective, Affordable Therapies
10. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
11. Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 /PRNewswire/ ... to grow, with the publication of two papers this ... Otolaryngology – Head and Neck Surgery , ... both objective and subjective measures of sleep disordered breathing, ... for the reduction in obstructive sleep apnea severity and ...
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... conferences in September: Stifel Nicolaus Healthcare Conference Thursday, ... UBS Global Life Sciences Conference Wednesday, September 21, at 9:30 ... of each event will be available on the Investor Relations ...
... Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today ... presenting at two upcoming investor conferences taking place in New ... will present at the Rodman and Renshaw Annual Global Investment ... On Wednesday, September 14, Mr. Shortall will present at the ...
Cached Medicine Technology:Unilife to Participate in Two Investor Conferences 2
(Date:9/20/2014)... 2014 "As a nurse, patients always ask ... an inventor from Tamaqua, Pa. "The reason that they cannot ... of their chairs. My invention enables them to check oxygen ... Sensor to make it easier to monitor the contents of ... when the tank is low. It allows changeovers to be ...
(Date:9/20/2014)... September 20, 2014 QueenBeeTickets.com is ready ... star’s tour performances. She will visit many cities in ... until the 16th of April. , Click Here ... Tour tickets at QueenBeeTickets.com. , The star’s fans are ... see their favorite young singer in a live performance. ...
(Date:9/20/2014)... The first federal bellwether trial of a DePuy ... in the U.S. District Court, Northern District of Texas, ... the week opened in the DePuy Pinnacle Hip ... vice president, who discussed the clinical testing performed on ... According to Reuters, the executive stated that the Pinnacle ...
(Date:9/19/2014)... 2014 Nearly 780 Risperdal lawsuits are ... where a meeting took place to discuss the next ... in the court’s mass tort program. Attorneys for the ... week at the Complex Litigation Center in Philadelphia’s City ... proceedings. The Risperdal lawsuits filed against Johnson & Johnson ...
(Date:9/19/2014)... City, KS (PRWEB) September 19, 2014 ... is responding to families in regions of the Philippines being ... , More than 1,060 families evacuated to the nearest ... storm Fung-Wong brought heavy rain and gusty winds to portions ... Friday causing heavy flooding. Some homes filled with more than ...
Breaking Medicine News(10 mins):Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2
... Maureen Salamon HealthDay Reporter , TUESDAY, Aug. ... investigating injectable drugs to treat psoriasis -- an autoimmune ... medications are not linked to higher heart risks. ... information from drug makers impeded their ability to assess ...
... bowel disease (IBD), which affects more than 1 million ... response triggered by environmental factors, such as bacteria, in ... inflammation of the lining of the colon, is one ... IBD is prompted by different cytokines small signaling ...
... Reporter , TUESDAY, Aug. 23 (HealthDay News) -- A test ... are most likely to raise the risk of invasive cervical ... accurate for many women than the Pap test alone, a ... HPV-positive, using the HPV test alone appears to be enough, ...
... are to investigate whether the therapeutic effects of clay ... of anger, anxiety and depression. Academics are teaming ... gallery and local artists for the innovative project that ... offer to young people struggling with mental health problems. ...
... psychology department show that people who use more ... are viewed more negatively than those who use milder ... adults are more negative about using anti-aging methods than ... rapid growth of the anti-aging cosmetic industry, age concealment ...
... drug and mental disorders would benefit greatly from smoking ... be five times more successful at kicking the habit, ... Center has found. Smokers with these comorbid conditions ... have a more difficult time quitting and represent a ...
Cached Medicine News:Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:Novel cytokine protects mice from colitis 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 3Health News:Modelling emotions: A potential new therapy for disturbed teenagers 2Health News:Modelling emotions: A potential new therapy for disturbed teenagers 3Health News:U of T research shows anti-aging techniques not yet viewed as acceptable 2Health News:Smokers with comorbid conditions need help from their doctor to quit 2Health News:Smokers with comorbid conditions need help from their doctor to quit 3
... prints labels up to 8.5 ... It is ideal for wide ... chemical drum labels, primary metal ... banner-sized labels and pallet and ...
... Korchek Technologies CareChek Tx, which ... a software device for blood ... match the patient to the ... bedside before administering a transfusion.The ...
... system ensures your patients are receiving the ... SafeTx uses the AutoPPI™ barcoded wristband to ... to transfusion. SafeTx checks that the correct ... for bedside paperwork and associated transcription errors. ...
... verification and laboratory specimen labeling system uses bar ... or nurse, the identity of the patient and ... made, a bar coded sample ID label is ... simplifies and eliminates the interface problems inherent with ...
Medicine Products: